TRIUMPH-5 results: retatrutide vs tirzepatide head to head
Reviewed 16 sourcesPublished by PepVault
TRIUMPH-5 puts retatrutide against tirzepatide in about 800 adults. What it tests, the numbers to beat, when it should report and how to read the result.

- Last reviewed
- Sources
- 16
- Questions
- 8
- Compounds
- 2
The short answer
TRIUMPH-5 has not reported yet (November 20, 2026). Eli Lilly's phase 3 trial gives about 800 adults with obesity retatrutide or tirzepatide, double-blind, and measures weight change at week 80. Primary completion is November 2026, per ClinicalTrials.gov. The numbers to beat: tirzepatide 15 mg averaged 20.9% weight loss at 72 weeks in its own trial, retatrutide 12 mg 25.0% at 80 weeks.
- No result yet as of November 20, 2026; primary completion is November 2026, per ClinicalTrials.gov.
- The bar from tirzepatide's own trial: -20.9% at 72 weeks counting everyone, -22.5% had all stayed on the drug.
- Read three things when it lands: the gap in points, the estimand behind the headline, and who stopped for side effects in each arm.
Evidence: Randomised phase 2 and phase 3 trials in people (NEJM, The Lancet), Lilly's topline releases for the newest numbers (company statements), the Zepbound label and ClinicalTrials.gov records. TRIUMPH-5 itself has no results yet, and retatrutide is investigational and not approved.

What does TRIUMPH-5 test?
TRIUMPH-5 is Eli Lilly's phase 3 trial of retatrutide against tirzepatide, the drug sold as Zepbound and Mounjaro1. It is randomized and double-blind: each person is assigned to one drug by chance, and neither the participants nor the investigators know which one1. The registry lists about 800 adults with obesity at 65 sites in the United States, Puerto Rico, Argentina, Germany and Poland1. Lilly calls it the head-to-head comparison of the two drugs10.
- The main measure (the primary endpoint): percent change in body weight from the start to week 801.
- The other measures, also at week 80: BMI, waist size, cholesterol, triglycerides, blood pressure, HbA1c (a three-month blood-sugar average), fasting insulin and a weight-related quality-of-life score1.
- Who was left out: anyone who had taken a weight-loss drug, over-the-counter ones included, in the 90 days before screening, or whose weight had changed by more than 5 kg (11 lb) in that time1.
- Who is in: Lilly describes the trial as adults with obesity with or without type 2 diabetes10.
- The doses: the registry names no dose for either arm1, so they are known only when Lilly reports.
Every comparison of the two drugs so far sets numbers from separate trials side by side. TRIUMPH-5 is the first time they meet in one study, under one set of rules.

How do retatrutide and tirzepatide differ?
Tirzepatide switches on two gut-hormone receptors, GIP and GLP-1, and GLP-1 is one of the body's own appetite regulators12. Retatrutide switches on those two and a third, the glucagon receptor11. In obese mice, the glucagon arm added extra energy burned on top of the eating-less effect of the other two11; that extra burn is an animal result. Tirzepatide is FDA-approved, and retatrutide is not approved anywhere10.
Commonly reported: appetite suppression on retatrutide that feels even stronger than on tirzepatide, stomach effects after each step-up that settle within a week or two, and a higher resting heart rate.
What did the earlier trials show?
These are the numbers TRIUMPH-5 will be read against, each from its own trial at the top dose. All ran against placebo except SURMOUNT-5, which put tirzepatide against semaglutide. The last column says how each trial counted people, which matters more than it looks (next section).
| Trial | Drug and dose | Weeks | Average weight change | Counted |
|---|---|---|---|---|
| SURMOUNT-1, no diabetes2 | Tirzepatide 15 mg | 72 | -20.9% (placebo -3.1%) | Everyone randomized |
| SURMOUNT-5, no diabetes4 | Tirzepatide 10 or 15 mg, highest tolerated | 72 | -20.2% (semaglutide -13.7%) | Not stated in the abstract |
| SURMOUNT-2, type 2 diabetes5 | Tirzepatide 15 mg | 72 | -14.7% (placebo -3.2%) | Everyone randomized |
| TRIUMPH-1, no diabetes7 | Retatrutide 12 mg | 80 | -25.0% (placebo -3.9%) | Everyone randomized |
| TRIUMPH-2, type 2 diabetes9 | Retatrutide 12 mg | 80 | -20.8% (placebo -4.0%) | Had all stayed on the drug |
Earlier, in the 48-week phase 2 trial, retatrutide 12 mg averaged -24.2% against -2.1% on placebo6. Retatrutide also has one head-to-head trial that has already read out, against semaglutide in type 2 diabetes: TRANSCEND-T2D-2, where 12 mg averaged 20.9% weight loss at 80 weeks against 9.4% on Ozempic 2 mg, had all stayed on the drug10.
PepVault's weight log keeps every weigh-in on one chart, so your own curve sits beside these trial averages when TRIUMPH-5 lands. Track your weight in PepVault
Why can't the separate trials settle it?
The cross-trial gap looks large, but four things differ between the trials, and each one moves the number.
- They count differently. Lilly reports two numbers per trial. The treatment-regimen estimand counts everyone randomized, whether they kept taking the drug or not; the efficacy estimand estimates the result had everyone stayed on it38. The second is always the bigger one.
- They ran for different lengths: 80 weeks for TRIUMPH-1 and TRIUMPH-5, 72 for SURMOUNT-1127. Most people who stayed on tirzepatide in SURMOUNT-1 had reached a weight plateau by week 7216, while people with a BMI of 35 or more who stayed on retatrutide 12 mg kept losing, to 30.3% at 104 weeks8.
- They started at different weights: the average BMI was 40.0 in TRIUMPH-18 and 38.0 in SURMOUNT-12.
- Diabetes shrinks the number: tirzepatide 15 mg averaged 14.7% with type 2 diabetes5 against 20.9% without2. If TRIUMPH-5 includes people with diabetes, as Lilly's description says10, both arms may land below their obesity-only records.
| Top dose, own trial | Everyone counted | Had all stayed on the drug |
|---|---|---|
| Tirzepatide 15 mg, SURMOUNT-1, 72 weeks | -20.9%2 | -22.5%3 |
| Retatrutide 12 mg, TRIUMPH-1, 80 weeks | -25.0%7 | -28.3%8 |
So the gap between separate trials is about 4 percentage points counting everyone, and about 6 counting people on the drug, with 8 extra weeks and heavier starters on retatrutide's side. TRIUMPH-5 takes all of that away: one population, one length, one way of counting.
What would count as a good result for retatrutide?
The bar is set here, before the result, so a headline can't move it. Read four things, in this order.
- The tirzepatide arm lands near its own record, about 21% counting everyone in people without diabetes, as in SURMOUNT-12 (20.2% in SURMOUNT-54). That shows the trial was a fair fight; a lower number is expected if many participants have diabetes5.
- The gap between the arms, in percentage points at week 80. For scale, tirzepatide beat semaglutide by 6.5 points at 72 weeks in SURMOUNT-5 (20.2% against 13.7%)4. A gap of 6 points or more would be a clear win on that scale; about 4 points would confirm what the separate trials suggest; 2 or 3 points would still favour retatrutide, but narrowly.
- The estimand behind the headline. Lilly's TRIUMPH releases lead with the efficacy estimand89, so set a headline retatrutide number against tirzepatide's 22.5%3, not its 20.9%.
- Who stopped for side effects, in each arm. In their own trials, 11.3% stopped on retatrutide 12 mg against 4.9% on placebo8, and 6.2% on tirzepatide 15 mg against 2.6%2. A weight win with twice the drop-out is a different choice from a win at equal tolerability.
One side effect is specific to watch. Dysesthesia, skin that feels unusual or uncomfortable to the touch, came in 12.5% on retatrutide 12 mg against 0.9% on placebo in TRIUMPH-1, and Lilly says the cases were generally mild to moderate and most resolved during treatment8. Zepbound's label, pooling its two main obesity trials, lists it in 0.4% on 15 mg against 0.1% on placebo12. TRIUMPH-5 will show both rates in the same trial.
When will TRIUMPH-5 report?
Primary completion, the date the last participant reaches the week-80 measure, is November 2026, an estimate per ClinicalTrials.gov; the whole study is estimated to end in December 2026, and the record was last updated in July 20261. Lilly has given no date for the results: its October 28 release calls the trial ongoing10.
Lilly's last three retatrutide readouts set a pattern: the topline press release came 6 to 15 weeks after primary completion.
| Trial | Primary completion (ClinicalTrials.gov) | Topline release | Gap |
|---|---|---|---|
| TRIUMPH-113 | April 6, 2026 | May 21, 20268 | 6 weeks |
| TRANSCEND-T2D-215 | August 27, 2026 | October 28, 202610 | 9 weeks |
| TRIUMPH-214 | June 16, 2026 | September 29, 20269 | 15 weeks |
On that pattern, a November primary completion puts the TRIUMPH-5 topline between mid-December 2026 and mid-March 2027. That is our arithmetic from the dates above, not a date from Lilly. Lilly set TRIUMPH-1's fuller results for the American Diabetes Association's Scientific Sessions8, and the paper came out in the New England Journal of Medicine on September 297. Lilly plans to file retatrutide with the FDA in the first quarter of 20279.
Has TRIUMPH-5 reported yet?
Not as of November 20, 2026. ClinicalTrials.gov shows no posted results1, and Lilly's releases name the trial only as ongoing10. This page is updated the day the topline lands, with the numbers, the source and the time of the update.
The result compares two drugs in a trial. It sets no dose for anyone, and retatrutide stays unapproved until the FDA rules on it10. For someone on tirzepatide today, the result changes nothing about the current prescription; a change of drug is a conversation with the prescriber.
PepVault logs each dose with its date, so a talk with your prescriber starts from your own record rather than memory. Log it in PepVault
How do you read the TRIUMPH-5 result when it lands?
- Open Lilly's release and check the trial name and number: TRIUMPH-5, NCT06662383.
- Find the primary endpoint: percent weight change at week 80, one number per arm.
- Check which estimand that number uses; the endnotes of Lilly's releases say.
- Subtract the tirzepatide number from the retatrutide number. That gap, in percentage points, is the result: set it against the 4-point (everyone counted) or 6-point (on the drug) gap between the separate trials.
- Find the doses each arm reached, and whether people with type 2 diabetes were included.
- Find the share who stopped for side effects in each arm, and the dysesthesia rate.
- Wait for the journal paper for what a release leaves out: the full side-effect tables and the confidence intervals around each number.
Sources
- TRIUMPH-5: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity. ClinicalTrials.gov NCT06662383. Eli Lilly and Company. clinicaltrials.gov
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. PubMed 35658024
- Eli Lilly and Company. Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss. Press release, June 4, 2022. prnewswire.com
- Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025. PubMed 40353578
- Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023. PubMed 37385275
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. PubMed 37366315
- Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. 2026. PubMed 42814954
- Eli Lilly and Company. Lilly's triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). Press release, May 21, 2026. prnewswire.com
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction (TRIUMPH-2). Press release, September 29, 2026. prnewswire.com
- Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial (TRANSCEND-T2D-2). Press release, October 28, 2026. prnewswire.com
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022. PubMed 35985340
- Zepbound (tirzepatide) injection, prescribing information. DailyMed, revised August 2026. dailymed.nlm.nih.gov
- TRIUMPH-1. ClinicalTrials.gov NCT05929066. Eli Lilly and Company. clinicaltrials.gov
- TRIUMPH-2. ClinicalTrials.gov NCT05929079. Eli Lilly and Company. clinicaltrials.gov
- TRANSCEND-T2D-2: Retatrutide compared with semaglutide in type 2 diabetes. ClinicalTrials.gov NCT06260722. Eli Lilly and Company. clinicaltrials.gov
- Horn DB et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025. PubMed 39800653
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.